Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

NCT03532451 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

43

Enrollment

OTHER

Sponsor class

Conditions

Bladder Cancer

Interventions

DRUG: Nivolumab
DRUG: Nivolumab/Lirilumab

Sponsor

PrECOG, LLC.

Collaborators

[object Object]